PSTI or DAX: PJT entered into definitive agreements with selected institutional and private investors to sell restricted common stock and warrants for aggregate gross proceeds of approximately $5.25M. Read more…
CYTX will offer 4,000,000 shares of common stock. Public offering Price: $4.50. Read more…
The University of California has entered the legal battle surrounding the use of human embryonic stem cells in research, filing a motion formally seeking to intervene in the case, 9/20/10. Read more…
The stem cell stocks index was up 2% on 9/9/10 post the Circuit Court appeals process with many gaining … and some losing: Read more…
A recent initiative by t
he Cell Therapy Foundation (CTF) tabulating clinical trials involving cell therapy recently identified BHRT’s MyoCell as 1 of only a few cell therapies that are presently in the Phase III stage of clinical trials Read more…
TIG has entered into an agreement with its academic partners, the Catholic University Leuven (KULeuven) and Ghent University (UGent), the Dutch company Therosteon and a consortium of investors for the creation of a new small molecule drug development company, Arcarios Read more…
The blended valuation model implies a pricing of $4.40 given the fully diluted shares outstanding. The Sum of the Parts estimation of $5.62 is discounted 10% and is significantly above this stocks current price of $1.49. Read more…
Optimism is the systematic tendency for people to be overly confident about the outcome of a potential event(s) Read more…
Net loss for Q2/10 was $2.3 M or $0.06 per share on weighted average outstanding of 37.6 M common shares. Read more…
STEM reported net loss of $4.61 M, or $0.04 per share. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.